21 CFR 210.1 - Status of Current Good Manufacturing Practice Regulations

What it says

The CGMP regulations set minimum requirements for the methods, facilities and controls used to manufacture, process and pack a drug, and a drug that is not manufactured in conformity with them is considered adulterated under the Federal Food, Drug, and Cosmetic Act, whatever the results of testing the finished product.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This provision is the legal basis for treating a CGMP failure as a product failure, meaning a batch can be considered adulterated even if every release test passed.
• The word minimum matters, the regulations set a floor, and current good manufacturing practice is expected to keep pace with what is current in the industry.
• It explains why inspection findings about systems and procedures can carry the same regulatory weight as a failed test result.

What FDA inspectors look for

• Whether the facility's methods, facilities and controls actually meet the CGMP minimums across all of its operations.
• Whether a firm's reliance on passing release testing is accompanied by genuine control of the process that made the batch.
• Whether quality systems keep pace with current industry practice rather than reflecting only historical expectations.

Related regulations